The Tuberculosis Drug Accelerator at year 10: what have we learned?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 34226736.
- Also identified by DOI 10.1038/s41591-021-01442-2 and PMC identifier 10478072.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The Tuberculosis Drug Accelerator, an experiment designed to facilitate collaboration in TB drug discovery by breaking down barriers among competing labs and institutions, has reached the 10-year landmark. We review the consortium’s achievements, advantages and limitations and advocate for application of similar models to other diseases.
Medical subject headings
- Antitubercular Agents
- Drug Design
- Tuberculosis